Transcompartmental inflammatory responses in humans: IV versus endobronchial administration of endotoxin*

Crit Care Med. 2014 Jul;42(7):1658-65. doi: 10.1097/CCM.0000000000000320.

Abstract

Objectives: Transcompartmental signaling during early inflammation may lead to propagation of disease to other organs. The time course and the mechanisms involved are still poorly understood. We aimed at comparing acute transcompartmental inflammatory responses in humans following lipopolysaccharide-induced pulmonary and systemic inflammation.

Design: Randomized, double-blind, placebo-controlled, crossover study.

Setting icu subjects: Healthy male volunteers.

Interventions: Fifteen volunteers (mean age, 23; SD, 2 yr) received Escherichia coli endotoxin (lipopolysaccharide, 4 ng/kg) IV or endobronchially on two different study days. Groups were evaluated by bronchoalveolar lavage at baseline (0 hr) and 2, 4, 6, 8, or 24 hours postchallenge. Cardiorespiratory variables were continuously recorded throughout the study day, and plasma and bronchoalveolar lavage fluid markers of inflammation were measured.

Measurements and main results: IV endotoxin elicited a systemic inflammatory response with a time-dependent increase and peak in tumor necrosis factor-α, interleukin-6, and leukocyte counts (all p < 0.001). Furthermore, a delayed (6-8 hr) increase in bronchoalveolar lavage fluid interleukin-6 concentration (p < 0.001) and alveolar leukocyte count (p = 0.03) and a minor increase in bronchoalveolar lavage fluid tumor necrosis factor-α were observed (p = 0.06). Endobronchial endotoxin was followed by progressive alveolar neutrocytosis and increased bronchoalveolar lavage fluid tumor necrosis factor-α, interleukin-6, and albumin (all p < 0.001); a systemic inflammatory response was observed after 2-4 hours, with no change in plasma tumor necrosis factor-α.

Conclusions: Acute lung or systemic inflammation in humans is followed by a transcompartmental proinflammatory response, the degree and differential kinetics of which suggests that the propagation of inflammation may depend on the primary site of injury.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / immunology
  • Administration, Intravenous
  • Adult
  • Biomarkers
  • Bronchoalveolar Lavage
  • Double-Blind Method
  • Drug Administration Routes
  • Endotoxins / immunology*
  • Hemodynamics
  • Humans
  • Inflammation / immunology
  • Inflammation Mediators / immunology*
  • Lipopolysaccharides / immunology*
  • Lung Diseases / immunology*
  • Male
  • Pneumonia / immunology
  • Systemic Inflammatory Response Syndrome / immunology*
  • Time Factors

Substances

  • Biomarkers
  • Endotoxins
  • Inflammation Mediators
  • Lipopolysaccharides
  • endotoxin, Escherichia coli